Cargando…

Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

SIMPLE SUMMARY: Programmed death-ligand 1 (PD-L1) expression in tumor tissue is a predictor for the efficacy of immune checkpoint inhibitors. We have previously reported that PD-L1 positive rate on circulating tumor cells (CTCs) in non-small cell lung cancer patients at baseline was correlated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeda, Mio, Koh, Yasuhiro, Teraoka, Shunsuke, Sato, Koichi, Oyanagi, Jun, Hayata, Atsushi, Tokudome, Nahomi, Akamatsu, Hiroaki, Ozawa, Yuichi, Endo, Katsuya, Higuchi, Masayuki, Nakanishi, Masanori, Ueda, Hiroki, Yamamoto, Nobuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150706/ https://www.ncbi.nlm.nih.gov/pubmed/34064720 http://dx.doi.org/10.3390/cancers13102290

Ejemplares similares

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system
por: Ikeda, Mio, et al.
Publicado: (2020)

Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients
por: Yagi, Satomi, et al.
Publicado: (2017)

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50
por: Ozawa, Yuichi, et al.
Publicado: (2020)

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency department
por: Furuta, Katsuyuki, et al.
Publicado: (2021)

Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
por: Akamatsu, Hiroaki, et al.
Publicado: (2022)

Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib
por: Shibaki, Ryota, et al.
Publicado: (2022)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
por: Tokudome, Nahomi, et al.
Publicado: (2020)

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
por: Akamatsu, Hiroaki, et al.
Publicado: (2021)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2021)

Differences in physical activity according to mMRC grade in patients with COPD
por: Hayata, Atsushi, et al.
Publicado: (2016)

Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab
por: Uchida, Naohiro, et al.
Publicado: (2017)

Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
por: Kanai, Osamu, et al.
Publicado: (2017)

Reproducibility of a Short Food Frequency Questionnaire for Japanese General Population
por: Imaeda, Nahomi, et al.
Publicado: (2007)

Daily, Weekly, Seasonal, Within- and Between-individual Variation in Nutrient Intake According to Four Season Consecutive 7 Day Weighed Diet Records in Japanese Female Dietitians
por: Tokudome, Yuko, et al.
Publicado: (2007)

Reproducibility of a Semi-quantitative Food Frequency Questionnaire in Japanese Female Dietitians
por: Imaeda, Nahomi, et al.
Publicado: (2007)

A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
por: Tomioka, Masayuki, et al.
Publicado: (2021)

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
por: Sakai, Kazuko, et al.
Publicado: (2020)

Long‐term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab
por: Oda, Risa, et al.
Publicado: (2020)

Relative Validity of a Short Food Frequency Questionnaire for Assessing Nutrient Intake versus Three-day Weighed Diet Records in Middle-aged Japanese
por: Tokudome, Yuko, et al.
Publicado: (2005)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
por: Kudo, Fumiaki, et al.
Publicado: (2018)

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
por: Akamatsu, Hiroaki, et al.
Publicado: (2021)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities
por: Matsubara, Junichi, et al.
Publicado: (2023)

Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes
por: Sato, Koichi, et al.
Publicado: (2022)

Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
por: Imakita, Takuma, et al.
Publicado: (2017)

A Case‐Control Study of Gastric Cancer and Diet in Northern Kyushu, Japan
por: Kono, Suminori, et al.
Publicado: (1988)

Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post‐surgical recurrence
por: Yaguchi, Daizo, et al.
Publicado: (2019)

Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature
por: Sawada, Koji, et al.
Publicado: (2019)

Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer
por: Yamasaki, Masahiro, et al.
Publicado: (2017)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Fabrication of cell plastics composed only of unicellular green alga Chlamydomonas reinhardtii as a raw material
por: Nakanishi, Akihito, et al.
Publicado: (2022)

Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR‐mutant non‐small cell lung cancer
por: Matsumoto, Yoshiya, et al.
Publicado: (2019)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

Distinctive features of degenerating Purkinje cells in spinocerebellar ataxia type 31
por: Yoshida, Kunihiro, et al.
Publicado: (2014)

A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis
por: Sakai, Katsuya, et al.
Publicado: (2017)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

Collagen type I induces EGFR‐TKI resistance in EGFR‐mutated cancer cells by mTOR activation through Akt‐independent pathway
por: Yamazaki, Shota, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qkdof7a7sa8279om8efpcirho0